MX2022014113A - Dosificacion y administracion del anticuerpo anti-ctla-4 activable. - Google Patents

Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Info

Publication number
MX2022014113A
MX2022014113A MX2022014113A MX2022014113A MX2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A
Authority
MX
Mexico
Prior art keywords
ctla
dosing
antibody
administration
activatable anti
Prior art date
Application number
MX2022014113A
Other languages
English (en)
Inventor
Leonard P James
Michelle Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022014113A publication Critical patent/MX2022014113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos de dosificación y administración de un anticuerpo anti-CTLA-4 activable, tal como un ipilimumab activable.
MX2022014113A 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable. MX2022014113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12
PCT/US2021/031670 WO2021231346A1 (en) 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
MX2022014113A true MX2022014113A (es) 2022-12-08

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014113A MX2022014113A (es) 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Country Status (13)

Country Link
US (1) US20230192856A1 (es)
EP (1) EP4149544A1 (es)
JP (1) JP2023526232A (es)
KR (1) KR20230009432A (es)
CN (1) CN115515633A (es)
AR (1) AR122043A1 (es)
AU (1) AU2021270513A1 (es)
BR (1) BR112022022713A2 (es)
CA (1) CA3178649A1 (es)
IL (1) IL298126A (es)
MX (1) MX2022014113A (es)
TW (1) TW202207982A (es)
WO (1) WO2021231346A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031032A1 (en) * 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008223A2 (pt) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
KR102504605B1 (ko) * 2016-12-07 2023-03-02 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
IL298126A (en) 2023-01-01
KR20230009432A (ko) 2023-01-17
EP4149544A1 (en) 2023-03-22
AR122043A1 (es) 2022-08-03
TW202207982A (zh) 2022-03-01
AU2021270513A1 (en) 2023-01-19
CA3178649A1 (en) 2021-11-18
BR112022022713A2 (pt) 2023-03-28
CN115515633A (zh) 2022-12-23
JP2023526232A (ja) 2023-06-21
US20230192856A1 (en) 2023-06-22
WO2021231346A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2020013169A (es) Conjugados de camptotecina.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2018016364A (es) Anticuerpos anti-pd-l1.
WO2018234793A3 (en) Antibodies
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
WO2018222722A3 (en) COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
PH12020551716A1 (en) Anti-ror antibody constructs
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2018081531A3 (en) Methods for human t-cell activation
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
CR20210088A (es) Composiciones de anticuerpos fcrn y métodos de uso de estos
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates
MX2022014113A (es) Dosificacion y administracion del anticuerpo anti-ctla-4 activable.
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
CR20230087A (es) Anticuerpos anti-notch2 y métodos de uso
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.